Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label evaluation of DCCR in Prader-Willi syndrome
2018-004216-22Phase 3Unknown
- Sponsor
- Soleno Therapeutics
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diazoxide in Prader-Willi syndrome (PWS), sponsored by Soleno Therapeutics. Primary endpoint: Long-term safety. Status: unknown.
02
Drugs
diazoxide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2018-004216-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004216-22.